Filed by Revance Therapeutics, Inc.
Pursuant to Rule 425 under the Securities Act of 1933, as amended
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934, as amended
Subject Company: Hint, Inc.
(Commission File No. 001-36297)
The following communication is being filed in connection with the acquisition of Hint, Inc. by Revance Therapeutics, Inc.
RVNC HintMD Announcement
Email from Aubrey Rankin and Vojin Kos to Certain HintMD Customers
Dear Valued Customer,
In 2014, we founded HintMD with the belief
that bringing dynamic subscriptions to aesthetics would revolutionize the industry. Today, we are excited to share the next step in achieving that goal. HintMD has entered into a definitive agreement to be acquired by Revance Therapeutics, Inc. We
are so grateful to you, our loyal customers, for your support and crucial feedback that enabled us to get to this point.
We are excited for the next
chapter at HintMD, where our shared vision with Revance is to deliver an open platform truly focused on driving patient loyalty to the physician. Revances innovative portfolio of injectable products will have a transformative
impact on the aesthetics industry and adding the HintMD platform will enable physicians to deliver prestige practice and patient experiences. For Revance, HintMD helps transform their commercial footprint in aesthetics and augments their portfolio
with the power of a vertically-integrated fintech platform.
We expect the acquisition to close in the third quarter of 2020 subject to approval of
the transaction by Hints stockholders which aligns perfectly with Revances planned launch of the RHA® Collection of dermal fillers!
What does this mean for you? Nothing changes in the short term and you will continue to receive the same excellent level of support you have come to expect
from us. Our customers are at the center of everything we do and our win-win-win philosophy of delivering solutions that benefit the patient, practice, and staff will
remain.